NCT00597285

Brief Summary

This study will look for evidence that a virus called HHV-6B may be related to seizures and to a form of brain injury called mesial temporal sclerosis that is associated with seizures. The study will use new, more sensitive brain scans to try to detect brain regions that might be affected by the virus and will examine cerebrospinal fluid (CSF, the fluid that bathes the brain and spinal cord) for evidence of the virus as well. Healthy volunteers and people with seizures uncontrolled by anti-epileptic drugs who are between 18 and 45 years of age may be eligible for this study. Candidates are screened with a physical examination and laboratory tests. Participants undergo the following procedures:

  • PET scan. This test uses a radioactive chemical called 18FDG, which is detected by the PET scanner to obtain images of the brain. The subject lies on a table with his or her head positioned in the scanner. A swimming cap with a small light reflector is placed on the head to monitor the position of the head during the scan. A catheter (plastic tube) is inserted into an artery at the wrist or elbow crease of the arm for obtaining blood samples during the scan, and a second catheter is placed in a vein in the other arm for injecting the 18FDG. The scan takes up to 2 hours. A second scan may be done over an additional 15 minutes.
  • MRI. This test uses a strong magnetic field and radio waves to obtain images of the brain. The subject lies on a table that can slide in and out of a metal cylinder surrounded by a magnetic field. Most scans last between 45 and 90 minutes.
  • Lumbar puncture. The subject sits upright or lies on a table with the knees curled to the chest for this procedure. A local anesthetic is injected to numb the skin and a needle is inserted in the space between the bones in the lower back where the CSF circulates below the spinal cord. A small amount of fluid is collected through the needle.
  • Blood tests. About 4 tablespoons of blood are drawn for viral tests.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2008

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 3, 2008

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

January 8, 2008

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 18, 2008

Completed
5.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2013

Completed
Last Updated

December 16, 2019

Status Verified

November 1, 2013

First QC Date

January 8, 2008

Last Update Submit

December 13, 2019

Conditions

Keywords

18-F-Fluoro-2-Deoxy-D-Glucose (FDG)Magnetic ResonanceEpilepsyHHV-6BHealthy VolunteerHV

Outcome Measures

Primary Outcomes (1)

  • Detection of evidence for HHV6 infection in CSF

Secondary Outcomes (1)

  • Detection of lesions on 7T compared to 3T MRI

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients will be avaluated for participation under screening protocol 01-N-0139.
  • Patients
  • Male and female subjects age 18 to 55
  • Subjects with seizures uncontrolled by antiepileptic drugs
  • Subjects with no other illnesses, or taking other substances or medicines that could interfere with the study
  • Healthy Controls
  • Male and female subjects age 18 to 55.

You may not qualify if:

  • Patient
  • Subjects who are pregnant or breast feeding.
  • Subjects with any medical condition that could interfere with the study.
  • Subjects who are taking drugs that significantly reduce blood clotting such as Coumadin or Warfarin.
  • Healthy Volunteers
  • Subjects who are pregnant or breast feeding
  • Subjects who have any medical condition or be taking any substance or medication that could interfere with the study
  • Subjects who are taking drugs that significantly reduce blood cloting such as Coumadin or Warfarin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Baker GA, Nashef L, van Hout BA. Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality. Epilepsia. 1997;38 Suppl 1:S1-8. doi: 10.1111/j.1528-1157.1997.tb04511.x.

    PMID: 9092951BACKGROUND
  • Begley CE, Famulari M, Annegers JF, Lairson DR, Reynolds TF, Coan S, Dubinsky S, Newmark ME, Leibson C, So EL, Rocca WA. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia. 2000 Mar;41(3):342-51. doi: 10.1111/j.1528-1157.2000.tb00166.x.

    PMID: 10714408BACKGROUND
  • Berg AT, Vickrey BG, Testa FM, Levy SR, Shinnar S, DiMario F, Smith S. How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol. 2006 Jul;60(1):73-9. doi: 10.1002/ana.20852.

    PMID: 16685695BACKGROUND

MeSH Terms

Conditions

Epilepsy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • William H Theodore, M.D.

    National Institute of Neurological Disorders and Stroke (NINDS)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
NIH

Study Record Dates

First Submitted

January 8, 2008

First Posted

January 18, 2008

Study Start

January 3, 2008

Study Completion

November 1, 2013

Last Updated

December 16, 2019

Record last verified: 2013-11-01

Locations